Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain: the CRIVERVA study
| dc.contributor.author | Trapero Bertran, Marta | |
| dc.contributor.author | Acera Pérez, Amèlia | |
| dc.contributor.author | Sanjosé Llongueras, Silvia de | |
| dc.contributor.author | Manresa Domínguez, Josep Maria | |
| dc.contributor.author | Rodríguez Capriles, Diego | |
| dc.contributor.author | Ana Rodriguez Martinez, Ana | |
| dc.contributor.author | Bonet Simó, Josep Maria | |
| dc.contributor.author | Sanchez Sanchez, Norman | |
| dc.contributor.author | Hidalgo Valls, Pablo | |
| dc.contributor.author | Diaz Sanchis, Mireia | |
| dc.date.accessioned | 2018-09-12T11:48:15Z | |
| dc.date.available | 2018-09-12T11:48:15Z | |
| dc.date.issued | 2017-02-14 | |
| dc.date.updated | 2018-07-24T12:10:49Z | |
| dc.description.abstract | Background: The aim of the study is to carry out a cost-effectiveness analysis of three different interventions to promote the uptake of screening for cervical cancer in general practice in the county of Valles Occidental, Barcelona, Spain. Methods: Women aged from 30 to 70 years (n = 15,965) were asked to attend a general practice to be screened. They were randomly allocated to one of four groups: no intervention group (NIG); one group where women received an invitation letter to participate in the screening (IG1); one group where women received an invitation letter and informative leaflet (IG2); and one group where women received an invitation letter, an informative leaflet and a phone call reminder (IG3). Clinical effectiveness was measured as the percentage increase in screening coverage. A cost-effectiveness analysis was performed from the perspective of the public health system with a time horizon of three to five years - the duration of the randomised controlled clinical trial. In addition, a deterministic sensitivity analysis was performed. Results are presented according to different age groups. Results: The incremental cost-effectiveness ratio (ICER) for the most cost-effective intervention, IG1, compared with opportunistic screening was (sic)2.78 per 1% increase in the screening coverage. The age interval with the worst results in terms of efficiency was women aged < 40 years. Conclusions: In a population like Catalonia, with around 2 million women aged 30 to 70 years and assuming that 40% of these women were not attending general practice to be screened for cervical cancer, the implementation of an intervention to increase screening coverage which consists of sending a letter would cost on average less than (sic)490 for every 1000 women. | |
| dc.format.extent | 8 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.pmid | 28196467 | |
| dc.identifier.uri | https://hdl.handle.net/2445/124483 | |
| dc.language.iso | eng | |
| dc.publisher | BioMed Central | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s12889-017-4115-0 | |
| dc.relation.ispartof | BMC Public Health, 2017, vol. 17, num. 194 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7/603019/EU//COHEAHR | |
| dc.relation.uri | https://doi.org/10.1186/s12889-017-4115-0 | |
| dc.rights | cc by (c) Trapero Bertran et al., 2017 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
| dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | |
| dc.subject.classification | Càncer de coll uterí | |
| dc.subject.classification | Anàlisi cost-benefici | |
| dc.subject.other | Cervix cancer | |
| dc.subject.other | Cost effectiveness | |
| dc.title | Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain: the CRIVERVA study | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1